Vigabatrin (Epilepsy)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)6.93 [1.26, 38.13]0%4 studies8812not evaluable ROB13.34 [1.83; .]
Major congenital malformations6.93 [1.26, 38.13]0%4 studies8812not evaluable ROB13.34 [1.83; .]
Limb defects23.44 [1.00, 547.07]-1 study26not evaluable ROB46.37 [1.07; .]
Neural Tube Defects39.12 [1.43, 1070.14]-1 study16not evaluable ROB77.74 [2.21; .]
Oro-facial clefts39.12 [1.43, 1070.14]-1 study16not evaluable ROB77.74 [2.21; .]
3 non statistically significant endpoints reported in only one study